Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

BioNTech SE

Co-Diagnostics

Moderna

Pfizer

Vaxart

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Why Coronavirus Stocks Are Zooming Higher Today

NVAX stock has had a turbulent 2021, but with its Covid-19 vaccine expected to go into product in Q4, growth looms. The post Plenty of Upside Potential Looms Ahead of Novavax Stock's Bumpy Road appeared first on InvestorPlace.

Plenty of Upside Potential Looms Ahead of Novavax Stock's Bumpy Road

Moderna and Novavax are leading Biotech companies who are expected to be major competitors in the COVID-19 vaccine market moving forward. While Moderna has a strong head start in the market in 2021, Novavax's impending entry is likely to offer stiff competition.

Moderna And Novavax: Competing For Global Domination In The Vaccines Market

Investors were increasingly confident that the company's COVID-19 vaccine would be successful.

Why Novavax Stock Soared 90% in the First Half of 2021

AstraZeneca

Johnson & Johnson

Based on company forecasts, Wall Street estimates, and author guestimates, the top coronavirus vaccine developers will bring in billions of dollars in sales this year.

COVID-19 Vaccines: How Much Revenue Will Each Drugmaker Generate in 2021?

Marathon Digital Holdings

Nikola

Triple-digit revenue growth awaits this popular trio of companies next year.

These Stocks Will See Sales More Than Double in 2022, According to Wall Street

Investors appear to be worried about the impact of the delta variant.

Why Novavax Stock Dropped This Week

COVID-19 concerns are driving the vaccine stocks higher.

Why Moderna and Novavax Stocks Are Jumping Today

Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.

Vaccine Stocks Fall as Delta Becomes Dominant Variant in US

The company finally got some good news about its vaccine production schedule.

Why Novavax Was Up 44% in June

Inovio Pharmaceuticals

Ocugen, Inc.

Stock markets moved slightly higher despite general worries.

With COVID-19 Variant Threats Rising, Why Are Vaccine Stocks Falling?

Novavax, Inc. (NASDAQ:NVAX) shares tumbled lower Wednesday after retail traders were able to push the stock lower. Vaccine stocks were very volatile today, and many are trading lower amid possible profit-taking as there are COVID-19 delta variant concerns.

Why Did Novavax Stock Get Slammed Today?

Today's significant selloff appears to be tied at least in part to some large stock sales made by the company's CEO earlier this month. The post NVAX Stock: One Big Reason Novavax Is Struggling Today appeared first on InvestorPlace.

NVAX Stock: One Big Reason Novavax Is Struggling Today

Novavax published results of its U.S. phase 3 trials for its Covid-19 vaccine in mid-June, noting that the shot was over 90% effective overall and 100% effective against moderate and severe disease, roughly in line with Covid vaccine leaders such as Pfizer and Moderna. Although the shot is likely.

Can Novavax Rise To The Manufacturing Challenge?

Novavax should take off as its successful Covid-19 vaccine spreads. NVAX stock is worth at least 50% more, given a mixture of analysts' estimates and comp analysis.

Novavax Stock Should Take Off as Its Successful Covid-19 Vaccine Spreads

NVAX stock is beginning to look like all the good news is priced in. However, a successful Covid-19 vaccine may be a catalyst for other vaccines.

The Real Value of Novavax Lies in Its Pipeline, Not the Pandemic

GAITHERSBURG, Md., July 6, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2021 financial results and operational highlights on Thursday, August 5, 2021, following the close of U.S. financial markets.

Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021

On June 14, Novavax announced that its Covid-19 vaccine, officially called "NVX-CoV2373," proved to be 93% effective against the Coronavirus and its variants in a phase 3 clinical trial. The vaccine was 100% effective against severe versions of Covid-19.

NVAX Stock Is Not For The Faint Of Heart

In the latest trading session, Novavax (NVAX) closed at $217.22, marking a +0.68% move from the previous day.

Novavax (NVAX) Gains But Lags Market: What You Should Know

It involves producing a vaccine in great volume.

This is Novavax's Biggest Challenge Right Now

Cummins

Value stocks have a knack for outperforming during the early stages of an economic recovery.

3 Value Stocks That'll Make You Richer in July (and Beyond)

Is the U.S. Buying Too Many COVID Vaccine Doses?

Let's use recent efficacy data as a starting point.

Can Novavax Beat Moderna and Pfizer in Preventing Severe COVID?

Novavax has made material progress since the disappointing lows of early May 2021.

Novavax Needs A 1:6 Share Split, For An Inviting Opportunity

Wall Street expects gains in the coming year.

News for Novavax Stock (NVAX)